ArticleCancers2010
Models of hepatocellular carcinoma and biomarker strategy.
Article in Cancers, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 27 citations in OpenAlex.
- LDN-57444 sensitizes hepatocellular carcinoma cells to sorafenib by promoting ferroptosis through histone deacetylase 2 (HDAC2) inhibition.Biology direct · 2026Article
- Ameliorative Effect ofInternational journal of molecular sciences · 2023Article
- Expression and Functionality of Connexin-Based Channels in Human Liver Cancer Cell Lines.International journal of molecular sciences · 2021Article
- Ameliorative Effects ofAntioxidants (Basel, Switzerland) · 2021Article
- Chemoembolizing hepatocellular carcinoma with microsphere cored with arsenic trioxide microcrystal.Drug delivery · 2020Article
- Characterizing responsive and refractory orthotopic mouse models of hepatocellular carcinoma in cancer immunotherapy.PloS one · 2019Article
- Silencing of CDCA5 inhibits cancer progression and serves as a prognostic biomarker for hepatocellular carcinoma.Oncology reports · 2018Article
- Localized microbubble cavitation-based antivascular therapy for improving HCC treatment response to radiotherapy.Cancer letters · 2017Article
- Up-regulation ofOncotarget · 2017Article
- Anti-cancer effects of Ajwa dates (Phoenix dactylifera L.) in diethylnitrosamine induced hepatocellular carcinoma in Wistar rats.BMC complementary and alternative medicine · 2017Article
- Creation of a murine orthotopic hepatoma model with intra-abdominal metastasis.Gastroenterology and hepatology from bed to bench · 2016Article
- Relating hepatocellular carcinoma tumor samples and cell lines using gene expression data in translational research.BMC medical genomics · 2015Article
- Contrast ultrasound imaging for identification of early responder tumor models to anti-angiogenic therapy.Ultrasound in medicine & biology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The overwhelming need to improve preclinical models in oncology has stimulated research efforts to refine and validate robust orthotopic models that closely mimic the disease population and therefore have the potential to better predict clinical outcome with novel therapies. Sophisticated technologies including bioluminescence, contrast enhanced ultrasound imaging, positron emission tomography, computed tomography and magnetic resonance imaging have been added to existing serum- and histology-based biomarkers to assist with patient selection and the design of clinical trials. The rationale for the use of human hepatocellular carcinoma (HCC) cell lines, implementation of xenograft and orthotopic animal models and utilization of available biomarkers have been discussed, providing guidelines to facilitate preclinical research for the development of treatments for HCC patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.